首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1649643

多發性硬化症市場規模、佔有率和成長分析（按藥物類別、診斷、給藥途徑、分銷管道、最終用戶和地區）—2025-2032 年產業預測

Multiple Sclerosis Market Size, Share, and Growth Analysis, By Drug Class (Immunomodulators, Immunosuppressants), By Diagnosis, By Route of Administration, By Distribution Channel, By End-Users, By Region - Industry Forecast 2025-2032

出版日期: 2025年02月02日 | 出版商:

SkyQuest | 英文 214 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球多發性硬化症市場規模價值 260.4 億美元，預計將從 2024 年的 266.4 億美元成長到 2032 年的 319.5 億美元，預測期內（2025-2032 年）的複合年成長率為 2.3%。

由於多發性硬化症 (MS) 盛行率不斷上升以及對研發的重視程度不斷提高，預計該疾病治療市場將經歷顯著成長。多發性硬化症的特徵是免疫介導的中樞神經系統損害，引起疲勞、麻木和認知障礙等症狀。單株抗體在治療中發揮著至關重要的作用，目前正在進行臨床試驗以開發創新治療方法。全球對人源化單株抗體和免疫抑制劑的需求正在激增，反映出有效治療 MS 的緊迫性。製藥公司和學術機構之間的合作研究協議進一步活性化了市場活動，將 MS 藥物開發定位為醫療保健領域投資和創新的主要領域。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分析市場佔有率
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Biogen Inc.（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
Key Developments
Merck KGaA（Germany）
Bayer AG（Germany）
Johnson & Johnson（United States）
AbbVie Inc.（United States）
TG Therapeutics, Inc.（United States）
Acorda Therapeutics, Inc.（United States）
Alkermes plc（Ireland）
H. Lundbeck A/S（Denmark）
Eli Lilly and Company（United States）
GlaxoSmithKline plc（United Kingdom）
Pfizer Inc.（United States）
Celgene Corporation（United States）
Mallinckrodt Pharmaceuticals（United Kingdom）
UCB SA（Belgium）
Orion Corporation（Finland）

結論和建議

簡介目錄

Product Code: SQMIG35G2271

Global Multiple Sclerosis Market size was valued at USD 26.04 billion in 2023 and is poised to grow from USD 26.64 billion in 2024 to USD 31.95 billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

The market for multiple sclerosis (MS) treatments is poised for significant growth, driven by the increasing prevalence of the disease and a heightened focus on research and development. MS, characterized by immune-mediated damage to the central nervous system, leads to symptoms like fatigue, numbness, and cognitive issues. Monoclonal antibodies play a pivotal role in treatment, with ongoing clinical trials aimed at developing innovative therapies. The demand for humanized monoclonal antibodies and immunosuppressive drugs is surging globally, reflecting the urgency for effective MS management. Collaborative research agreements between pharmaceutical companies and academic institutions have further intensified market activity, positioning MS medication development as a key area of investment and innovation in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Market Segments Analysis

Global Multiple Sclerosis Market is segmented by Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users and Region. Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons and Others. Based on Diagnosis, the market is segmented into Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Market

The rising prevalence of multiple sclerosis is a key factor fueling the growth of the global market. This condition is divided into four distinct types: relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS). The high incidence rates associated with these forms are likely to significantly influence market trends and dynamics throughout the forecast period. As more individuals are diagnosed and require effective treatments, the demand for innovative therapies and medical solutions is expected to increase, ultimately driving the overall expansion of the multiple sclerosis market on a global scale.

Restraints in the Global Multiple Sclerosis Market

Conversely, the Global Multiple Sclerosis market is likely to experience constraints that could hinder its growth. The exorbitant expense associated with the treatment of multiple sclerosis poses a significant barrier to market expansion. Additionally, developing countries are grappling with a shortage of trained professionals and insufficient healthcare infrastructure, further complicating access to treatment. The COVID-19 pandemic has also led to a decline in clinical visits, and a general lack of awareness among the public regarding the disease can impede market progress. These factors collectively are expected to restrain the market's growth throughout the forecast period from 2022 to 2029.

Market Trends of the Global Multiple Sclerosis Market

The global Multiple Sclerosis (MS) market is witnessing a robust trend driven by significant investments in research and development (R&D) aimed at innovative treatments. Pharmaceutical companies, including emerging players like Pipeline Therapeutics, are increasingly focusing on advanced therapeutic candidates, such as PIPE-307, a selective M1 receptor antagonist currently undergoing clinical trials. The proliferation of research collaborations between pharmaceutical firms and academic institutions further enhances the landscape, spurring growth. As companies diversify their pipelines with novel treatment options, this renewed emphasis on R&D is poised to catalyze market expansion, providing patients with more effective treatment choices and improving overall outcomes in MS management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Multiple Sclerosis Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Immunomodulators
Immunosuppressants
Interferons
Others

Global Multiple Sclerosis Market Size by Diagnosis & CAGR (2025-2032)

Market Overview
Magnetic Resonance Imaging (MRI)
Simple Electrical Stimulation Tests
Lumbar Puncture
Others

Global Multiple Sclerosis Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Parenteral
Others

Global Multiple Sclerosis Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Multiple Sclerosis Market Size by End-Users & CAGR (2025-2032)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Multiple Sclerosis Market Size & CAGR (2025-2032)

North America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- US
- Canada
Europe (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TG Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkermes plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments